Form 4: Ionis Pharmaceuticals Executive Stock Transaction

EVP and Chief Business Officer Joseph Baroldi reported the vesting of restricted stock units and a subsequent sale to cover tax obligations.

Summary

• Joseph Baroldi, EVP and Chief Business Officer of Ionis Pharmaceuticals, acquired 10,837 shares of common stock on April 15, 2026, through the vesting of restricted stock units (RSUs).
• On April 16, 2026, the reporting person sold 5,619 shares at a weighted average price of $74.56 per share.
• The sale was executed automatically to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, the reporting person holds 46,535 shares directly and 4,347 shares indirectly through a spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is a routine administrative action related to tax obligations rather than a discretionary change in investment sentiment.

Positives

• The transaction reflects the standard vesting of equity compensation, aligning executive interests with long-term shareholder value.

Negatives

• The sale of shares, even for tax purposes, reduces the executive's direct equity stake in the company.

Risks

• The reporting person remains subject to market volatility regarding the remaining 46,535 shares held directly.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that this is a routine regulatory disclosure regarding executive compensation and tax compliance, common in the biotechnology sector where equity-based incentives are a primary component of executive remuneration.

Comparison to Industry Standards

• The use of automatic sell-to-cover transactions for tax obligations is a standard practice among executives at major pharmaceutical companies like Amgen, Gilead, and Biogen.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a pre-planned tax-related sale.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Insider Trading, Form 4, Executive Compensation, Restricted Stock Units